Tag: Precision medicine for gynecologic cancers

Home / Precision medicine for gynecologic cancers

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

  June 2024: Pembrolizumab (Keytruda, Merck) has been authorized by the Food and Drug Administration for the treatment of adult patients with primary, advanced, or recurrent endometrial cancer...
precision-medicine-for-gynecologic-cancers

Scan the code